GlassScriptPhysician profile
Marissa E Magsino
NPI 1295917763
$2,186.53
in general payments reported to CMS, 2019-2025
12 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $180 · 2021: $178 · 2022: $324 · 2024: $58.65 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $733.49 | 2025 | Assure Wcd |
| Novo Nordisk INC | $477.54 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Merz North America, INC. | $441.65 | 2019-2025 | |
| Clarus Therapeutics INC. | $134.28 | 2020-2021 | |
| Axsome Therapeutics, INC. | $122.10 | 2025 | Symbravo |
| Kvk-Tech, INC. | $78.82 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $73.36 | 2019-2021 | |
| Lilly USA, LLC | $35.04 | 2024-2025 | Zepbound, Mounjaro |
| Amag Pharmaceuticals, INC. | $33.11 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $24.16 | 2019 | |
| Galderma Laboratories, L.P. | $18.73 | 2025 | |
| Acella Pharmaceuticals, LLC | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Magsino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.